Karyopharm Therapeutics Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €263.59M -17.0% €18.78M -63.8% 7.1% -0.092 pp N/A N/A
    (estimated) €317.77M +60.8% €51.94M -184.2% 16.3% +0.48 pp N/A N/A
    (estimated) €197.67M +39.8% -€61.69M -45.8% -31.2% +0.49 pp N/A N/A
    (estimated) €141.35M +12.1% -€113.78M +0.6% -80.5% +0.092 pp N/A N/A
    (estimated) €126.07M +0.8% -€113.08M +71.7% -89.7% -0.37 pp N/A N/A
    €125.13M -0.5% -€65.84M -46.6% -52.6% +0.45 pp -€109.71M +37.3% -87.7% -0.24 pp
    €125.81M -7.0% -€123.29M -13.4% -98.0% +0.072 pp -€79.89M -38.0% -63.5% +0.32 pp
    €135.33M -25.1% -€142.41M +33.2% -105.2% -0.46 pp -€128.75M +47.4% -95.1% -0.47 pp
    €180.77M +94.1% -€106.91M -36.8% -59.1% +1.2 pp -€87.36M -36.7% -48.3% +1.0 pp
    €93.12M +164.3% -€169.10M -1.7% -181.6% +3.1 pp -€137.92M -16.0% -148.1% +3.2 pp
    €35.23M +34.8% -€171.96M +11.9% -488.1% +1.0 pp -€164.23M +21.6% -466.1% +0.51 pp
    €26.14M +1,790.1% -€153.71M +38.3% -588.1% +74 pp -€135.05M +112.8% -516.7% +41 pp
    €1.38M +942.2% -€111.13M +17.7% -8,036.4% +630 pp -€63.46M -12.6% -4,589.1% +500 pp
    €132.68K -38.4% -€94.41M -7.3% -71,153.9% -240 pp -€72.65M -9.0% -54,753.9% -180 pp
    €215.39K +9.2% -€101.82M +56.0% -47,272.4% -140 pp -€79.79M +90.5% -37,045.2% -160 pp
    €197.29K -40.8% -€65.29M +123.2% -33,090.4% -240 pp -€41.88M +60.8% -21,228.4% -130 pp
    €333.42K -39.0% -€29.25M +113.7% -8,771.8% -63 pp -€26.05M +96.5% -7,812.1% -54 pp
    €546.22K +317.1% -€13.69M +54.1% -2,506.0% +43 pp -€13.26M +88.3% -2,427.1% +29 pp
    €130.96K -€8.88M -6,783.6% -€7.04M -5,377.0%

    Notifications